Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40

Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121

Eye Diseases Spur More M&A in July

At least three of the deals announced so far in July have targeted companies or compounds that treat eye diseases. The first was Biogen Inc. (NASDAQ: BIIB) and its $124 million deal with Applied Genetic Technologies (NASDAQ: AGTC) for the worldwide commercialization rights to one clinical-stage and one pre-clinical therapeutic program. Last week, Allergan Inc. (NYSE: AGN) paid $125 million for Oculeve, Inc., a medical device company focused on new technologies for dry eye disease. Then, rival Valeant Pharmaceuticals International (NYSE: VRX) paid an undisclosed amount for the global rights to EyeGate Pharmaceuticals’ (OTCQB: EYEG) EyeGate II Delivery System and EGP-437 combination product... Read More »

Centene Snares Health Net for $6.8 Billion

And so it begins. The managed care merry-go-round picked up speed last week as Centene Corporation (NYSE: CNC) announced it would pay approximately $6.8 billion (including $500 million of debt) to acquire a smaller rival, Health Net, Inc. (NYSE: HNT). A day later, Aetna (NYSE: AET) and Humana (NYSE: HUM) agreed to a deal priced at $37 billion, including debt. That leaves Anthem Inc. (NYSE: ANTM) in pursuit of Cigna (NYSE: CI), which had turned down its latest offer of $47.5 billion the week before. All eyes are now on Molina Healthcare (NYSE: MOH) and WellCare Health Plans (NYSE: WCG), waiting to see if they are targets, or merger partners. Or both. Read More »

Second Quarter Health Care M&A Spending Tanks

It’s still early yet, but we can say with confidence that the second quarter of 2015 doesn’t hold a candle to last year’s second quarter, at least dollar-wise. Last year, deal volume and value hit all-time highs for all previous Q2s, coming in at 325 deals and $135.8 billion in spending on those deals. This year, deal volume was fairly steady at 312 (remember, these are preliminary figures for Q2:15) but deal value plummeted 60% to $54.2 billion. We’ll have more details in the July issue of Health Care M&A News, but in the meantime, here are the biggest deals of Q2:15.  Read More »

Juno Therapeutics Teams up with Celgene

Celgene Corporation (NASDAQ: CELG) made a big bet on a small company last week, when it agreed to pay nearly $1 billion to Juno Therapeutics (NASDAQ: JUNO) for a 10-year collaboration on immunotherapies targeting cancer and autoimmune diseases. The real price is $999,803,496 and consists of an upfront payment of $150 million, and the purchase of 9.1 million shares of JUNO common stock at a price of $93.00 per share. That’s a pretty generous offer, considering Juno’s stock price was bumping along around $54.00 late last week. Juno will be responsible for research and development in North America, and retains commercialization rights there. Celgene will be responsible for development and... Read More »

Madison Dearborn Buys into Rehab Products

Chicago-based private equity firm Madison Dearborn Partners plunked down $715 million for Patterson Medical, a division of Patterson Companies (NASDAQ: PDCO). The parent company wants to focus on its dental and animal health businesses, and was looking for a buyer. Patterson Medical provides rehabilitation, assistive and splinting products around the world, which is clearly not great fit. Price-to-EBITDA was a mere 1.06x. Read More »

Zimmer-Biomet Merger Spurs More Deals

After more than a year of regulatory reviews in the United States and Europe, Warsaw, Indiana-based Zimmer Holdings (NYSE: ZMH) and its cross-town rival Biomet, Inc., finally tied the knot on June 24, 2015. In April 2014, when the deal was first announced, the price was put at $13.35 billion. At closing, management stated that the value of the deal was approximately $14 billion. The combined company will be known as Zimmer Biomet Holdings, Inc., and will trade on the NYSE and SIX under the ticker symbol ZBH. The acquisition was conditioned upon the sale of some Zimmer and Biomet assets, and hot on the heels of the closing, Smith & Nephew (NYSE: SNN) acquired Zimmer’s Unicompartmental... Read More »

Top Deals in June 2015 Aren’t So Big

Healthcare M&A in June 2015 hasn’t been dead slow, but it certainly hasn’t kept pace with previous months’ totals. With 83 deals and $14.8 billion in spending, June 2015 lags far behind June 2014’s 120 transactions and $59.2 billion in spending. That said, we’re writing this on the day the U.S. Supreme Court found for the defendant (the Obama administration) in King v. Burwell, which means there could be a few very large deals announced between now and next week—particularly in the managed care sector, where the Big Five health insurers have already made plans to consolidate into the Big Three (see last week’s story in Health Care Deal News). For now, here are the five biggest deals... Read More »

Sabra Buys the NMS Portfolio

Sabra Health Care REIT (NASDAQ: SBRA) plunked down $234 million for four skilled nursing facilities, known as the “NMS Portfolio,” all located in Maryland. The four skilled nursing facilities, with a combined total of 678 beds, specialize in transitional care and medically complex post-surgical, ventilator and dialysis patients. Sabra will enter into a triple-net master lease agreement with the current operator on three of the facilities and a triple-net lease agreement on the fourth, which is encumbered by a HUD loan. They will have an initial term of 15 years, two 10-year renewal options and annual rent escalators equal to the great of 2.50% or CPI, but not to exceed 2.75%. Initial yield... Read More »